The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2025 | Strategies being explored to enhance the efficacy of CAR T-cells in hematological malignancies
Massimiliano Mazza, PhD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy, highlights several approaches being explored to enhance CAR-T efficacy for the treatment of hematological malignancies. These include novel costimulatory domains, faster production methods, and allogeneic or off-the-shelf CAR-T therapies, such as gene-edited T-cells and in vivo production, which could decrease the cost of this therapy. This interview took place at the SOHO Italy Annual Conference 2025 in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
